Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BIO GREEN MED SOLUTION INC (BGMS)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$0.86-3.36%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
880.80 → 880.80 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for BGMS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain disciplined capital allocation | A supporting condition in BIO GREEN MED SOLUTION INC's published investment case. The stated target is quarterly dividend of $0.15 per preferred share; improve cash flow. | Intact | operating cash flow remains negative beyond 2026-Q4 | Cash from operations: $0 FY2026-Q2; GAAP. Published target: quarterly dividend of $0.15 per preferred share; improve cash flow. Target period is not explicitly aligned with this observation. Jun 30, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making business with a volatile management record, not a proven durable compounder. The thesis is currently intact and recently shifted from mixed to mildly favorable, but confidence is medium and the business risk remains high.
The evidence points to BGMS being cheap versus peers, but valuation confidence is low because the company is loss-making. No priced-in fragility flags fired, though the snapshot does not specify what expectations the market assumes.
Near term, lower general and administrative expenses show progress on costs, while fire safety revenue fell from the first quarter to the second quarter of 2026. The planned Future NRG business combination remains on track for expected completion in the fourth quarter of 2026, but the business remains loss-making and small-cap, with a history of a deep miss.
Over the next one to three years, the thesis depends on completing the Future NRG combination and turning stated priorities into steadier business results. A weakening jobs trend could increase pressure on cyclical names, while continued earnings strength from healthcare bellwethers could support the sector backdrop; misses or lower guidance from those companies could remove that support.
The multi-year view remains intact but fragile: cost reduction and a favorable sector backdrop are positives, while losses, uneven execution, and high business risk remain central. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Address legal and Nasdaq listing challenges | It works on legal issues to keep its Nasdaq listing. | Under Pressure | Nasdaq delisting or unresolved litigation by 2027 | Nasdaq notice received vs target: maintain listing Company received Nasdaq notice on minimum bid price compliance on 2026-11-04. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow revenue through strategic agreements | A primary condition in BIO GREEN MED SOLUTION INC's published investment case. The stated target is >= $743,000 revenue in 2026-Q1. | Broken | revenue falls below $743,000 in any quarter after 2026-Q1 | Revenue: $336,000 FY2026-Q2; GAAP. Published target: >= $743,000 revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026336,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$880.80 → $880.80 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-25 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-26 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-27 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-28 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-29 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-30 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-07-31 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-01 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-02 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-03 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-04 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-05 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-06 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-07 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-08 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-09 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-10 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-11 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-12 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-13 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-14 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-15 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-16 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-17 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-18 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-19 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-20 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-21 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-22 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-23 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-24 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-25 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-26 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-27 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-28 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-29 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-30 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-08-31 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-01 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-02 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-03 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-04 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-05 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-06 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-07 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-08 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-09 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-10 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-11 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-12 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-13 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-14 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-15 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-16 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-17 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-18 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-19 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-20 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-21 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-22 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-23 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-24 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-25 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-26 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-27 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-28 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-29 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-09-30 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-01 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-02 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-03 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-04 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-05 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-06 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-07 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-08 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-09 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-10 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-11 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-12 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-13 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-14 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-15 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-16 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-17 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-18 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-19 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-20 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-21 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-22 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-23 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-24 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-25 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-26 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-27 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-28 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-29 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-30 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-10-31 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-11-01 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-11-02 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-11-03 | $880.80 | $80,582,000 | 1 / 1 |
| 2026-11-04 | $880.80 | $80,582,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.